Sort
82,697 grants matching “vaccine development”
Pathogenesis of E. coli and Shigella infections in human enteroid models
$1,581,962James B Kaper · University Of Maryland Baltimore · P01 · FY2019 · AI
Pathogenesis of E. coli and Shigella infections in human enteroid models
$1,581,962James B Kaper · University Of Maryland Baltimore · P01 · FY2020 · AI
Pathogenesis of E. coli and Shigella infections in human enteroid models
$1,581,962James B Kaper · University Of Maryland Baltimore · P01 · FY2017 · AI
North Carolina STI/TM Cooperative Research Center
$1,581,499University Of North Carolina Chapel Hill · U19 · FY2005 · AI
Structural Biology of Influenza Epitopes
$1,581,260Audray Harris · National Institute Of Allergy And Infectious Diseases · ZIA · FY2018 · AI
NIAID Centers of Excellence for Influenza Research and Response: Universal Influenza Research Activities
$1,581,241Walter Orenstein · Emory University · N01 · FY2022 · AI
Vaccines, Immunoprophylaxis, and Immunotherapy for SARS
$1,581,212Kanta Subbarao · Niaid Extramural Activities · Z01 · FY2007 · AI
Natural History of HPV Infection to Neoplasia
$1,580,769Anna-Barbara None Moscicki · University Of California, San Francisco · R37 · FY2009 · CA
Molecular Analysis of Tuberculosis Immunity
$1,580,467William Robert Jacobs · Albert Einstein College Of Medicine, Inc · P01 · FY2015 · AI
The molecular pathogenesis of varicella zoster virus infection
$1,580,109Donald Gilden · University Of Colorado Denver · P01 · FY2011 · AG
Dynamics and Evolution of Immune Responses to Influenza Viruses
$1,579,938Rustom Noshir Antia · Emory University · U19 · FY2019 · AI
New class of PBP inhibitors to address PBP2-mediated resistance in Neisseria gonorrhoeae
$1,579,751Denis Marc Daigle · Venatorx Pharmaceuticals, Inc. · R01 · FY2022 · AI
MYCOBACTERIUM TUBERCULOSIS (MTB) QUALITY ASSESSMENT PROGRAM (TBQA)
$1,578,677Jeanette Coffin · Midwest Research Institute · N01 · FY2023 · AI
Sex differences in immune responses to vaccine and circulating strains of influenza in healthcare workers
$1,578,357Andrew S. Pekosz · Johns Hopkins University · U54 · FY2022 · AG
LIVE, ATTENUATED, RECOMBINANT VACCINE - WEST NILE VIRUS
$1,577,110Acambis, Inc. · R01 · FY2002 · AI
Development of simple formulations for vaccine use
$1,577,096Arya Biragyn · National Institute On Aging · ZIA · FY2020 · AG
COMBINED VACCINE STRATEGIES FOR THE PREVENTION OF AIDS
$1,576,586Therion Biologics Corporation · P01 · FY2001 · AI
IGF::OT::IGF SIMIAN VACCINE EVALUATION UNITS
$1,576,546Ranajit Pal · Advanced Bioscience Laboratories, Inc. · N01 · FY2016 · AI
Human immune signatures of latent MTB infection, active disease and BCG vaccination
$1,576,438Bjoern Peters · La Jolla Institute For Immunology · U19 · FY2017 · AI
Clinical Research Support for the CCR
$1,576,085Robert Wiltrout · Division Of Basic Sciences - Nci · ZID · FY2009 · CA
Novel VLP-Based Mucosal and Sytemic HIV Vaccines
$1,575,400University Of Alabama At Birmingham · U19 · FY2003 · AI
Protective Mechanisms Against Pandemic Respiratory Virus
$1,575,294Stanford University · U19 · FY2003 · AI
American and Asian Centers for Arboviral Research and Enhanced Surveillance (A2CARES)
$1,575,273Eva Harris · University Of California Berkeley · U01 · FY2021 · AI
B CELL EPITOPE DISCOVERY AND MECHANISMS OF ANTIBODY PROTECTION.
$1,575,000Donna Williams · Washington University · N01 · FY2022 · AI
Lung Cancer Program
$1,574,861Giuseppe Giaccone · Division Of Basic Sciences - Nci · ZIA · FY2009 · CA